5441722025-01-012025-03-315441722025-03-315441722024-03-315441722024-04-012025-03-315441722025-01-012025-03-31in-capmkt:OtherExpenses1Member5441722024-04-012025-03-31in-capmkt:OtherExpenses1Member5441722025-01-012025-03-31in-capmkt:ReportableSegments1Member5441722025-01-012025-03-31in-capmkt:ReportableSegments2Member5441722025-01-012025-03-31in-capmkt:ReportableSegments3Member5441722025-01-012025-03-31in-capmkt:ReportableSegments4Member5441722024-04-012025-03-31in-capmkt:ReportableSegments1Member5441722024-04-012025-03-31in-capmkt:ReportableSegments2Member5441722024-04-012025-03-31in-capmkt:ReportableSegments3Member5441722024-04-012025-03-31in-capmkt:ReportableSegments4Member5441722025-01-012025-03-31in-capmkt:ReportableSegments1Member5441722025-01-012025-03-31in-capmkt:ReportableSegments2Member5441722025-01-012025-03-31in-capmkt:ReportableSegments3Member5441722025-01-012025-03-31in-capmkt:ReportableSegments4Member5441722024-04-012025-03-31in-capmkt:ReportableSegments1Member5441722024-04-012025-03-31in-capmkt:ReportableSegments2Member5441722024-04-012025-03-31in-capmkt:ReportableSegments3Member5441722024-04-012025-03-31in-capmkt:ReportableSegments4Member5441722025-01-012025-03-31in-capmkt:ReportableSegments1Member5441722025-03-31in-capmkt:ReportableSegments1Member5441722025-01-012025-03-31in-capmkt:ReportableSegments2Member5441722025-03-31in-capmkt:ReportableSegments2Member5441722025-01-012025-03-31in-capmkt:ReportableSegments3Member5441722025-03-31in-capmkt:ReportableSegments3Member5441722025-01-012025-03-31in-capmkt:ReportableSegments4Member5441722025-03-31in-capmkt:ReportableSegments4Member5441722025-01-012025-03-31in-capmkt:ReportableSegments1Member5441722025-03-31in-capmkt:ReportableSegments1Member5441722025-01-012025-03-31in-capmkt:ReportableSegments2Member5441722025-03-31in-capmkt:ReportableSegments2Member5441722025-01-012025-03-31in-capmkt:ReportableSegments3Member5441722025-03-31in-capmkt:ReportableSegments3Member5441722025-01-012025-03-31in-capmkt:ReportableSegments4Member5441722025-03-31in-capmkt:ReportableSegments4Member5441722025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15441722024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15441722025-01-012025-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15441722024-04-012025-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15441722025-01-012025-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares544172INDGNNOTLISTEDINE065X01017Indegene LimitedMain BoardEquity2024-04-012025-03-312025-04-282025-04-21INRMillionsQuarterlyFourth quarterMulti segment2025-04-2817:30:002025-04-2817:53:00trueCash Flow IndirectDeclaration of unmodified opinion2025-01-012025-03-31UnauditedConsolidated7556000000256000000781200000000048510000003100000020700000012300000006319000000149300000001493000000438000000-12100000031700000001176000000000011760000002600000012020000001202000000047900000024.914.88004.914.88Notes to the Statement of Consolidated Financial Results for the quarter and year ended 31 March 2025 <BR> All amounts in INR millions, except share data and where otherwise stated <BR> 1. The above Consolidated Financial Results of Indegene Limited formerly Indegene Private Limited the Company or the Parent or the Holding Company together with its affiliates collectively the Group, have been prepared in accordance with Indian Accounting Standards Ind AS 34 Interim Financial Reporting, recognition and measurement principles of Indian Accounting Standards Ind AS prescribed under Section 133 of the Companies Act, 2013, as amended, read with the relevant rules issued thereunder and in terms of Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015 the Regulations. Due to rounding off, the numbers presented throughout may not add up precisely to the totals. in the financial information denote amounts less than INR0.50 million. <BR> 2. The above Consolidated Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 28 April 2025. The figures for the quarter ended 31 March 2025 are the balancing figures between audited figures in respect of full financial year and published unaudited year to date figures upto the end of the third quarter of the current financial year, which were subject to limited review. <BR> 3. The Consolidated Financial Results for the quarter and year ended 31 March 2025, are available on the National Stock Exchange of India Limited URL www.nseindia.com, the BSE Limited website URL www.bseindia.com and on the Companys website URL www.indegene.cominvestorrelations. <BR> 4. During the year, the Company has completed Initial Public Offer IPO of 40,766,550 equity shares of face value of INR2 each at an issue price of INR452 per share Issue price of INR422, including a share premium of INR420 per share, for employee quota towards fresh issue, comprising fresh issue of 16,833,818 shares aggregating to INR7,600 and offer for sale of 23,932,732 shares by selling shareholders aggregating to INR10,818. The equity shares of the Company are listed in National Stock Exchange of India Limited NSE and BSE Limited BSE on 13 May 2024. The Company has received an amount of INR7,244 net of Companys share of IPO expenses of INR356, retained in the Public Offer Account to the extent unpaid from the proceeds of the fresh issue. Out of the Company s shares of IPO expenses INR319 has been adjusted to securities premium. <BR> The utilization of IPO proceeds of INR7,244 is summarized below <BR> Particulars , Amount to be utilised as per offer document, Utilisation as on 31032025 , Unutilised as on 31032025, Amounts in INR Mn <BR> a. Repaymentprepayment of indebtedness of one of our Subsidiaries, ILSL Holdings, Inc. 3913 3950 37 <BR> b. Funding the capital expenditure requirements of our Company and our Material Subsidiary, Indegene, Inc. 1029 185 844 <BR> c. General corporate purposes and inorganic growth 2302 2088 214 <BR> The Company has repaid loan of USD 47.20 Million INR3950 outstanding in the books of ILSL Holdings Inc. material subsidiary, in line with Object 1 of the offer document. The amount utilised over and above the maximum amount specified as per the offer document is due to exchange rate fluctuation as on the date of offer document and as on the date of payment. <BR> Out of the net proceeds which were unutilised as at 31 March 2025, INR980 are temporarily invested in fixed deposits, INR41 is held in the Company s monitoring account, while the balance amount is held in the public offer account towards the Company s share of expenses related to issue. <BR> 2024-04-012025-03-31AuditedConsolidated28393000000107200000029465000000000181520000002200000008020000004898000000240720000005393000000053930000001491000000-1650000001326000000040670000000000406700000025600000043230000004323000000047900000022566700000017.1517.020017.1517.02Other Expenses1230000000Other Expenses48980000001349000000360000003565000000186200000000133000000133000000898000000116000000795900000001289700000075140000002410000000133600000001260000002428300000010170000002530000000033259000000479000000256770000002615600000026156000000087300000087300000058500000014580000000170000009170000009340000001443000000237700000025100000006770000008100000056450000007103000000332590000005. During the year ended 31 March 2025, 521,330 options have been granted under Employee Restricted Stock Unit plan 2020 RSU 2020, 243,973 options have been granted under Employee Stock Option Plan 2020 ESOP 2020 and 39,571 options have been granted under Company Share Option Plan 2022 CSOP 2022 to the eligible employee of the Company. 527,331 options under RSU 2020 plan and 211,722 options under ESOP 2020 plan have been exercised during the year. <BR> 6. Exceptional items <BR> On 12 October 2022, the Group had obtained control of Cult Health LLC by acquiring 100% interest to enhance the Groups commercialization portfolio adding market development and brand strategy competencies along with patient engagement platforms. The acquisition was consummated for a consideration of INR5,347. The contingent consideration is based on the performance of Cult Health LLC during the fiscal year beginning 01 April 2023 and ending 31 March 2026 and range of contingent consideration payable is between Nil to INR3,040. Cult Health LLC is part of Omnichannel Activation segment. <BR> The Group carried out remeasurement of the change in fair value of contingent consideration towards earnout payout, which was measured at its fair value on acquisition and recognised a resultant gain of INR935. Change in fair value movement of contingent consideration has been recognized as an exceptional item during the previous year ended 31 March 2024. Further, the Group also carried out the assessment of recoverable value of the investments made in Cult Health LLC owing to reduction in revenues from certain customers and its impact on the future cash flows. The recoverable amount of this CGU estimated to be lower than carrying value, resulting into an impairment charge of INR911. The impairment charge had been recognized as an exceptional item during the previous year ended 31 March 2024. <BR> 7. The Group, during the year, basis the Managements assessment remeasurement of the fair value of the contingent consideration payable, has reversed contingent consideration pertaining to acquisition of Cult Health LLC and Trilogy Writing & Consulting GmbH Trilogy amounting to INR103 and INR55, respectively and has been accounted for the same as other income. Further, the Group had invested in TriloDocs GmbH at the time of acquisition of Trilogy via convertible loan of EUR 1.5 Mn. Based on assessment of recoverability of the loan given to TriloDocs GmbH aggregating to INR135, the Group has fully provided for the same during the year ended 31 March 2025 and accounted it as other expenses. <BR> 8. Acquisition of MJL Communications Group Ltd On 25 March 2025, the Group had obtained control of MJL Communications Group Ltd MJL by acquiring 100percent of its shares. MJL specializes in brand strategy, omnichannel campaigns, and patient engagement. It provides communication solutions for pharmaceutical and healthcare brands using their proprietary Illuminate strategy. MJL focuses on strategic insights, scientific storytelling, and content development to support healthcare communications. The acquisition was consummated for a consideration of INR398 which includes earnout payment of INR149. The contingent consideration is based on the performance of MJL during the fiscal year beginning 01 April 2025 and ending 31 March 2027 and range of contingent consideration payable is between Nil to INR172. The Group believes that the acquisition will enable the Group to leverage the above capabilities and expand across its customer accounts. The purchase price allocation for MJL is provisional and will be finalized within the measurement period, but in no event later than one year following the date of acquisition.Enterprise Medical Solutions2107000000Enterprise Commercial Solutions4255000000Omnichannel Activation967000000Others*227000000Enterprise Medical Solutions8025000000Enterprise Commercial Solutions15871000000Omnichannel Activation3477000000Others*1020000000755600000028393000000755600000028393000000Enterprise Medical Solutions585000000Enterprise Commercial Solutions915000000Omnichannel Activation147000000Others*-100000000Enterprise Medical Solutions2081000000Enterprise Commercial Solutions3484000000Omnichannel Activation458000000Others*-3290000001547000000569400000031000000220000000230000008100000014930000005393000000Enterprise Medical Solutions0Enterprise Commercial Solutions0Omnichannel Activation0Others*0000Enterprise Medical Solutions0Enterprise Commercial Solutions0Omnichannel Activation0Others*0000Notes to the Statement of Consolidated Financial Results for the year ended 31 March 2025 Contd. <BR> 9. Operating Segment <BR> The Segment results of the Group has been prepared in accordance with IndAS 108 on Operating Segments. The Group has identified business segments industry practice as reportable segments. The reportable business segments comprise: 1 Enterprise Medical Solutions, 2 Enterprise Commercial Solutions, 3 Omnichannel Activation. <BR> Others mainly comprises of consultancy and clinical business. <BR> Operating segments are identified as components of an enterprise for which discrete financials information is available that is evaluated regularly by the chief operating decision maker. In deciding how to allocate resources and assessing performance, the Groups chief operating decision maker is the Chief Executive Officer and Executive Director. <BR> Assets and liabilities used in the Groups business are not identified to any of the operating segments, as these are used interchangeably between segments. Management believes that it is currently not practicable to provide segment disclosures relating to total assets and liabilities since a meaningful segregation of the available data is onerous. <BR> Other unallocable expenditure net of unallocable income for the quarter ended 31 March 2025 includes depreciation and amortisation expense INR 207 and unallocable expenses INR 72 net of other income INR 256. <BR> Other unallocable expenditure net of unallocable income for the year ended 31 March 2025 includes depreciation and amortisation expense INR 802 and unallocable expenses INR 351net of other income INR 1072. <BR> 10. The Board of Directors, in its meeting on 28 April 2025, have proposed a final dividend of INR2 per equity shares for the financial year ended 31 March 2025. The proposal is subject to the approval of shareholders at the ensuing Annual General Meeting and if approved would result in a cash outflow of approximately INR480. <BR> <BR> Statement of Cash Flow includes following aggregations: <BR> 1.Cash flows from Operating Activities: <BR> Other adjustments to reconcile profit loss includes <BR> a. Gain due to change in contingent consideration negative INR 162 <BR> b. Loss allowance of loan INR 135 <BR> c. Net gain on disposal fair valuation of investments negative INR 292 <BR> d. Expected credit loss on trade receivables and advances INR 18 <BR> <BR> 2.Cash flows from Investing Activities <BR> Other Inflow Outflows of cash includes <BR> a. Purchase of investments accounted using FVTPL negativeINR 52572 <BR> b. Proceeds from redemption of investments INR 47932 <BR> c. Investments in fixed deposits negative INR 18168 <BR> d. Redemption or maturity of fixed deposit INR 16908 <BR> <BR> 3. Cash flows from Financing Activities <BR> Proceeds from issuing shares is net of share issue expenses1940000000-820000000034300000000000061100000008020000000107000000000170000000501000000174000000000-3010000000062600000060190000000001600000000044190000000001113000000000003000000000000000000000000004860000000-5900000000-6827000000007327000000000000403100000000103000000318000000028750000004670000005700000052400000018860000002410000000Remeasurement of defined benefit obligation-39000000-39000000Remeasurement of defined benefit obligation-21000000-21000000-10000000-5000000Exchange differences on translating the financial statements of foreign operations5500000055000000Exchange differences on translating the financial statements of foreign operations2720000002720000000026000000256000000AuditedtrueB S R & Co. LLPtrue2025-07-31